Skip to Main Content

Author Details

Johannes C van der Mijn
New York Presbyterian Hospital
2012
24
11
PMIDPaper TitleJournal TitlePublished Year
36722045NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.Cancer Biol Ther2023
37217526Novel genetically engineered mouse models for clear cell renal cell carcinoma.Sci Rep2023
35231161The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.Mol Oncol2022
35726553Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).Mol Carcinog2022
31865180Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma.Transl Oncol2020
32024067Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome.Cancers (Basel)2020
31898184NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.Invest New Drugs2020
31290707Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.J Urol2019
31815952Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.PLoS One2019
31469605Reply by Authors.J Urol2019
30018133Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.Oncologist2018
30126372Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection.BMC Bioinformatics2018
29515400Lactic Acidosis in Prostate Cancer: Consider the Warburg Effect.Case Rep Oncol2017
28442448Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection.J Proteomics2017
26815723Sunitinib activates Axl signaling in renal cell cancer.Int J Cancer2016
27980342Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.Exp Mol Med2016
27418963Novel drugs that target the metabolic reprogramming in renal cell cancer.Cancer Metab2016
27444431Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.J Neurooncol2016
25890253Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics.J Proteomics2015
25187478Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Oncologist2014
25491250Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.J Extracell Vesicles2014
25457974Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.Drug Resist Updat2014
22379477Irinotecan-induced dysarthria.Case Rep Oncol2012
22418023Codon-optimized Luciola italica luciferase variants for mammalian gene expression in culture and in vivo.Mol Imaging2012
  • 1 - 24 of 24

Recommended Authors

Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 0
Margaret Cancer Center
Career Start Year 2016
Number of shared co-authors 0
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Institute of Urologic Oncology, University of California Los Angeles
Career Start Year 2012
Number of shared co-authors 0
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 0
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 0
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 1
University of Southern California
Career Start Year 2004
Number of shared co-authors 0
Center for Applied Proteomics and Molecular Medicine, George Mason University
Career Start Year 2004
Number of shared co-authors 0
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Mayo Clinic Arizona
Career Start Year 2002
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2002
Number of shared co-authors 4
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 2
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 6
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 1
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1998
Number of shared co-authors 0
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Washington University
Career Start Year 1994
Number of shared co-authors 1
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 3
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 2
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Co-authored papers 8
Sandra and Edward Meyer Cancer Center
Co-authored papers 7
Meyer Cancer Center
Co-authored papers 7
Englander Institute for Precision Medicine
Co-authored papers 4
New York-Presbyterian Hospital
Co-authored papers 3
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 2
Institute for Computational Biomedicine
Co-authored papers 2
Weill Cornell Medical College
Co-authored papers 2
Vrije Universiteit Amsterdam
Co-authored papers 1
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 1
Co-authored papers 1
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 1
Weill Cornell Medical College
Co-authored papers 1
The Netherlands Cancer Institute
Co-authored papers 1
Meyer Cancer Center
Co-authored papers 1
Dana-Farber Cancer Institute
Co-authored papers 1
Columbia University, United States Bureau of Educational and Cultural Affairs Fulbright Program, University of Piraeus, Weill Cornell Medical College, Weill Cornell Medicine
Co-authored papers 1
Weill Cornell Medical College
Co-authored papers 1
Weill Cornell Medical College.
Co-authored papers 1
Englander Institute for Precision Medicine
Co-authored papers 1
Englander Institute for Precision Medicine
Co-authored papers 1
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 1
Englander Institute for Precision Medicine
Co-authored papers 1